Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7051790 in relapsed ED SCLC
NCT02913443Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of iadademstat in small cell lung cancer (SCLC) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events at 18 weeks and Number of Participants with Dose-Limited Toxicities at 21 days. Started Dec 2016; status: completed.
02
Drugs
iadademstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02913443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913443.